Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1967 1
1969 3
1971 1
1972 3
1973 1
1974 1
1976 2
1978 2
1979 1
1980 3
1981 1
1982 3
1983 1
1984 3
1985 4
1986 7
1987 6
1988 5
1989 6
1990 6
1991 2
1992 8
1993 8
1994 15
1995 11
1996 12
1997 15
1998 10
1999 8
2000 13
2001 12
2002 18
2003 20
2004 15
2005 21
2006 27
2007 21
2008 29
2009 41
2010 37
2011 41
2012 49
2013 52
2014 62
2015 78
2016 48
2017 38
2018 44
2019 65
2020 60
2021 68
2022 66
2023 70
2024 24

Text availability

Article attribute

Article type

Publication date

Search Results

1,050 results

Results by year

Filters applied: . Clear all
Page 1
Loss of copy numbers of retrotransposons (HERVK) on chromosome 7p11.2 impacts EGFR (Epidermal Growth Factor Receptor)-induced phenotypes for platinum sensitivity and long-term survival in ovarian cancer-A study from the OVCAD consortium.
Fromhage G, Obermayr E, Bednarz-Knoll N, Van Gorp T, Welsch E, Polterauer S, Braicu EI, Mahner S, Sehouli J, Vergote I, Concin N, Kurtz S, Steinbiss S, Torge A, Zeillinger R, Wölber L, Brandt B. Fromhage G, et al. Among authors: van gorp t. Int J Cancer. 2024 May 6. doi: 10.1002/ijc.34976. Online ahead of print. Int J Cancer. 2024. PMID: 38709956
Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program.
van Leeuwen LPM, Grobben M, GeurtsvanKessel CH, Ellerbroek PM, de Bree GJ, Potjewijd J, Rutgers A, Jolink H, van de Veerdonk FL, van Gils MJ, de Vries RD, Dalm VASH; VACOPID Research Group. van Leeuwen LPM, et al. Front Immunol. 2024 Apr 18;15:1390022. doi: 10.3389/fimmu.2024.1390022. eCollection 2024. Front Immunol. 2024. PMID: 38698851 Free PMC article.
Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration.
Tusch E, Ryom L, Pelchen-Matthews A, Mocroft A, Elbirt D, Oprea C, Günthard HF, Staehelin C, Zangerle R, Suarez I, Vehreschild JJ, Wit F, Menozzi M, d'Arminio Monforte A, Spagnuolo V, Pradier C, Carlander C, Suanzes P, Wasmuth JC, Carr A, Petoumenos K, Borgans F, Bonnet F, De Wit S, El-Sadr W, Neesgaard B, Jaschinski N, Greenberg L, Hosein SR, Gallant J, Vannappagari V, Young L, Sabin C, Lundgren J, Peters L, Reekie J; D:A:D cohort study; RESPOND cohort study. Tusch E, et al. Clin Infect Dis. 2024 Apr 26:ciae228. doi: 10.1093/cid/ciae228. Online ahead of print. Clin Infect Dis. 2024. PMID: 38663013
Longitudinal determinants of employment status in people with relapsing-remitting multiple sclerosis.
van Egmond EEA, van der Hiele K, de Rooij MJ, van Gorp DAM, Jongen PJ, van der Klink JJL, Reneman MF, Beenakker EAC, van Eijk JJJ, Frequin STFM, de Gans K, Hoitsma E, Gerlach OHH, Mostert JP, Verhagen WIM, Visser LH, Middelkoop HAM. van Egmond EEA, et al. Among authors: van gorp dam. IBRO Neurosci Rep. 2024 Apr 15;16:518-526. doi: 10.1016/j.ibneur.2024.04.002. eCollection 2024 Jun. IBRO Neurosci Rep. 2024. PMID: 38660124 Free PMC article.
Appraisal of the IADT fellowship - A member survey.
Onetto J, Sobczak M, Skapetis T, Kahler B, Tishkina O, Van Gorp G, O'Connell AC. Onetto J, et al. Among authors: van gorp g. Dent Traumatol. 2024 Apr 23. doi: 10.1111/edt.12962. Online ahead of print. Dent Traumatol. 2024. PMID: 38651791
Exome sequencing identifies HELB as a novel susceptibility gene for non-mucinous, non-high-grade-serous epithelial ovarian cancer.
Dicks EM, Tyrer JP, Ezquina S, Jones M, Baierl J, Peng PC, Diaz M, Goode E, Winham SJ, Dörk T, Van Gorp T, De Fazio A, Bowtell D, Odunsi K, Moysich K, Pavanello M, Campbell I, Brenton JD, Ramus SJ, Gayther SA, Pharoah PDP. Dicks EM, et al. Among authors: van gorp t. medRxiv [Preprint]. 2024 Apr 3:2024.04.02.24304968. doi: 10.1101/2024.04.02.24304968. medRxiv. 2024. PMID: 38633804 Free PMC article. Preprint.
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design.
Vergote I, Perez Fidalgo A, Valabrega G, Monk BJ, Herzog T, Cibula D, Colombo N, Pothuri B, Sehouli J, Korach J, Barlin J, Papadimitriou CA, van Gorp T, Richardson D, McCarthy M, Antill Y, Mirza MR, Li K, Kalyanapu P, Slomovitz B, Coleman RL. Vergote I, et al. Among authors: van gorp t. Int J Gynecol Cancer. 2024 Apr 16:ijgc-2024-005412. doi: 10.1136/ijgc-2024-005412. Online ahead of print. Int J Gynecol Cancer. 2024. PMID: 38627035
1,050 results